Clinical

Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant (alloHSCT) may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.

The panelists highlight key takeaways for payors involved in MDS treatment.

Experts discuss how collaborative care drives optimal MDS treatment.

Asian and Hispanic patients with stage II or III noncardia gastric adenocarcinoma had significantly better overall survival following surgery compared with their White counterparts.

Key questions to ask patients during diagnosis of Demodex blepharitis to identify signs and symptoms of the condition are covered by Dr. Yeu.

As many as 116 million patients were impacted by large health data breaches this year; grassroots groups have begun leading the push to re-enroll patients denied Medicare coverage for bureaucratic reasons; a nationwide shortage of primary care clinicians is causing more distrust in the health care system.

A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.

The authors developed and validated an accurate, well-calibrated, easy-to-implement COVID-19 hospitalized patient deterioration index to identify patients at high or low risk of clinical deterioration.

Trajectory of patient outcomes for those diagnosed with bronchiectasis is explored by Dr Metersky.

Clostridioides difficile risk is significantly higher in Korean patients with inflammatory bowel disease (IBD), which is comparable to the trend observed in Western patients with IBD.

A panel of medical experts discuss the shift from intervention to prevention in the management of dry eye disease, as well as perspectives on resource allocation.

Experts provide a perspective on disparities in accessibility and outcomes based on the current socioeconomic landscape in health care.

More than 15.3 million Americans enrolled in health insurance under the Affordable Care Act for 2024, which is a 33% increase from last year; emergency contraception sales in the United States may spike by around 10% in the new year; top Biden administration officials met with prominent civil rights and public health leaders on Tuesday amid the decision to delay the menthol cigarette ban.

An in-depth look into what the drug is being used for and what has contributed to the shortage.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the emergence of targeted therapies for lung cancer and their ongoing impact on outcomes for certain patients.

Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.

Patients with immune-mediated thrombotic thrombocytopenic purpura (TTP) were found to have white matter damage in the frontal lobe and cingulate cortex that could affect short-term memory and depressive scores.

Patients with colorectal cancer (CRC) had reduced readmissions when treatment focused on preventing prolonged ileus, increasing the use of minimally invasive surgery, and preventing anastomotic leaks.

Coverage from The US Oncology Network Payer Transformation Summit, held September 27-29, 2023, in Atlanta, Georgia.

Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.

Key opinion leaders open a discussion surrounding CLL and SLL, and describing unique characteristics of each disease state.

Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical unmet needs in Dry Eye Disease (DED) therapies and explores the potential impact of new agents in addressing these challenges.

Medical professionals discuss strategies and best practices for recognizing and mitigating immunotherapy toxicities through multidisciplinary collaboration and use of monitoring technology.

Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.

The panel emphasizes the role of multidisciplinary tumor boards in optimizing oncology care in nonmelanoma skin cancers.